Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo<\/sub><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n MONDAY, June 6, 2022 (HealthDay News) — For patients with high-risk nonmetastatic breast cancer receiving standard therapy, the addition of metformin does not improve invasive disease-free survival, according to a study published in the May 24\/31 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Pamela J. Goodwin, M.D., from the University of Toronto, and colleagues examined whether administration of adjuvant metformin improves outcomes among patients with breast cancer without diabetes. A total of 3,649 patients with high-risk nonmetastatic breast cancer receiving standard therapy were enrolled between August 2010 and March 2013, with follow-up to October 2020.<\/p>\n The researchers found that after a second interim analysis, futility was declared for patients who were estrogen receptor and\/or progesterone receptor (ER\/PgR)-negative, so the primary analysis was conducted among 2,533 ER\/PgR+ patients, with a median follow-up of 96.2 months. Invasive disease-free survival events occurred in 465 ER\/PgR+ patients. The incidence rates for invasive disease-free survival events were 2.78 and 2.74 per 100 patient-years in the metformin and placebo groups, respectively; the corresponding incidence rates for death were 1.46 and 1.32 per 100 patient-years.<\/p>\n “Among patients with high-risk operable breast cancer without diabetes, the addition of metformin versus placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry; Apotex Canada provided in-kind donations of placebo and metformin. <\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n